Sanofi et al. back €47m series-B for MinervaX

Existing investors Novo Holdings, Repair Impact Fund, Sunstone Life Science Ventures and LF Investment also joined the round.

The proceeds will be used to advance the clinical development of MinervaX's novel group B streptococcus (GBS) vaccine through phase-II clinical trials, as well as manufacturing and regulatory preparation for phase-III.

The company's vaccine targets GBS, which is responsible for infections in pregnant women and nearly half of all life-threatening infections in newborns.

According to Crunchbase, MinervaX has so far raised a total of $81.5m in funding, including grants.

Company
Founded in 2010 and based in Hellerup, MinervaX is a biotechnology company developing a vaccine against GBS, which infects pregnant women and newborns.

The company has fewer than 10 employees and reported an EBITDA of DKK 27.3m (€3.6m) for 2019.

People
MinervaX – Per Fischer (CEO).
Wellington Partners – Karl Nägler (managing partner).
Sanofi Ventures – Christopher Gagliardi (director of investments).
Novo Seeds – Emmanuelle Coutanceau (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Nordics
• Healthcare
• Nordic venture
• Wellington Partners
• Denmark
• Sunstone Capital A/S